BiotechTube

Placebo + KVD900 600 mg + KVD900 300 mg

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hereditary Angioedema

Conditions

Hereditary Angioedema

Trial Timeline

Feb 22, 2022 → Dec 31, 2023

NCT ID
NCT05259917

About Placebo + KVD900 600 mg + KVD900 300 mg

Placebo + KVD900 600 mg + KVD900 300 mg is a phase 3 stage product being developed by KalVista Pharmaceuticals for Hereditary Angioedema. The current trial status is completed. This product is registered under clinical trial identifier NCT05259917. Target conditions include Hereditary Angioedema.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05259917Phase 3Completed

Competing Products

20 competing products in Hereditary Angioedema

See all competitors
ProductCompanyStageHype Score
KVD900KalVista PharmaceuticalsPhase 2
47
KVD824 + Placebo to KVD824KalVista PharmaceuticalsPhase 1
28
KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
72
SebetralstatKalVista PharmaceuticalsPre-clinical
18
KVD900 + Placebo to KVD900KalVista PharmaceuticalsPhase 1
28
SebetralstatKalVista PharmaceuticalsPre-clinical
18
KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tabletKalVista PharmaceuticalsPhase 1
28
KVD900 150 mg + KVD900 300 mg + KVD900 600 mgKalVista PharmaceuticalsPhase 3
72
KVD824 + Placebo to KVD824KalVista PharmaceuticalsPhase 2
47
KVD900 600 mg + Drug: KVD900 300 mgKalVista PharmaceuticalsPhase 3
72
Deferasirox FCTNovartisPhase 2
52
Canakinumab + PlaceboNovartisPhase 3
77
IlarisNovartisPre-clinical
23
Standard of Care for Haemophilia ARochePre-clinical
23
EmicizumabRochePhase 3
77
TafamidisPfizerPre-clinical
22
tafamidisPfizerPre-clinical
22
NitisinoneSwedish Orphan BiovitrumPre-clinical
22
NitisinoneSwedish Orphan BiovitrumPhase 1
32
NitisinoneSwedish Orphan BiovitrumPre-clinical
22

Other Products from KalVista Pharmaceuticals

KVD900 600 mg + Drug: KVD900 300 mgPhase 3
72
KVD900 600 mg + KVD900 300 mgPhase 3
72
KVD900 150 mg + KVD900 300 mg + KVD900 600 mgPhase 3
72
KVD824 + Placebo to KVD824Phase 2
47
KVD001 InjectionPhase 2
47